Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dinutuximab - National Cancer Institute/United Therapeutics Corporation

Drug Profile

Dinutuximab - National Cancer Institute/United Therapeutics Corporation

Alternative Names: Anti-GD2 monoclonal antibody ch14.18; Ch14.18; ch14.18-UTC; Chimeric anti-GD2 monoclonal antibody; Unituxin

Latest Information Update: 07 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer National Cancer Institute (USA); New Approaches to Neuroblastoma Therapy Consortium; St. John of God Foundation; United Therapeutics Corporation
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants; GD2 ganglioside inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuroblastoma
  • Phase II/III Small cell lung cancer
  • Discontinued Malignant melanoma

Most Recent Events

  • 29 Nov 2018 Registered for Neuroblastoma (Combination therapy, In adolescents, In children, In infants, Second-line therapy or greater) in Canada (IV)
  • 29 Nov 2018 United Therapeutics Corporation intends to launch dinutuximab, for the treatment of high-risk neuroblastoma in Canada, in first half of 2019
  • 16 Nov 2018 New Approaches to Neuroblastoma Therapy Consortium initiates enrolment in the NANT phase I trial for Neuroblastoma (Combination therapy, Second-line or greater therapy, In adolescents, In adults, In children, In infants) in USA (NCT02573896)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top